MedTrace Logo

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

NCT04615949 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-21

Study results available
· View outcomes & findings →

Summary

Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.

Conditions

Interventions

DRUG

Cannabidiol, pharmaceutically produced with < 5 ppm THC

CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food

DRUG

Placebo

Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food

Sponsors & Collaborators

  • Cardiol Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Dennis McNamara, MD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2022-11-30
Completion
2022-11-30
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04615949 on ClinicalTrials.gov